Chris Lau, Kapitall: A small biotech stock can be risky, but we found one taking full advantage of America's push to get in shape.
The bullish sentiment in Amarin Corporation (AMRN) is improving. Since reporting quarterly earnings last month that missed on consensus revenue estimates but beat on earnings, shares are now up 23%. Is the recovery going to hold, or will the rally be stopped short again?
[Read more from Kapitall: Online Gambling Stocks: Will the US Cash In?]
Solid second quarterAmarin generated revenue of $7.3 million, when you include the $1.8 million in the deferred net value of its FDA approved Vascepa (icosapent ethyl derived from fish oil). Combined with a weight loss program – a low-fat and low-cholesterol diet - Vascepa can help lower triglycerides and other fatty substances in the blood. Prescriptions for the medication rose to a normalized 47,335, up from 10,484 from the previous quarter. And in recent clinical trials, the company also reported that concentrations of VLDL (very-low-density lipoprotein) were reduced by 12.2% in subjects receiving the therapy for 12 weeks. Healthy balance sheet Amarin ended the second quarter with $149.4 million in cash as at June 30, 2013. This was helped by $121.1 million in equity financing. Prospects improving Access to Vascepa for clinicians is good, but the company continues to limit its availability. There were over 9,000 physicians prescribing Vascepa at the end of the second quarter. Amarin wants to focus only on the knowledgeable clinicians who are high prescribers of other lipid therapies. This improves the overall safety profile for the drug. On August 26, Amarin submitted a Supplemental New Drug Application for Novasep Group, an additional Vascepa active ingredient supplier. This will increase Amarin’s ability to supply and produce more Vascepa. Alternative investment Amarin is outperforming competitor Arena Pharmaceuticals (ARNA) in the one year period. This could be due to heavy short sellers weighing on Arena. Short float is 30.3% for Arena, compared to 14.75% for Amarin. Click on the interactive charts to see analyst ratings and stock prices over time. &amp;amp;amp;amp;amp;amp;amp;lt;p&amp;amp;amp;amp;amp;amp;amp;gt;Your browser does not support iframes.&amp;amp;amp;amp;amp;amp;amp;lt;/p&amp;amp;amp;amp;amp;amp;amp;gt;
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV